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Sir,
Decreased levels of the target enzyme thymidylate synthase (TS)
have been repeatedly associated with superior clinical outcome in
gastrointestinal cancers, including stomach cancer. In the study by
Goekkurt et al (2006), patients who possessed a TS 50 genotype
associated with low TS mRNA expression levels showed a trend for
superior survival time compared with those having TS genotypes
associated with high TS mRNA expression. A significant associa-
tion between clinical outcome to 5-fluorouracil (5FU)-based
chemotherapy in colorectal cancer and TS polymorphisms
was demonstrated when both TS polymorphisms within the
50 untranslated (UTR) region were contemporarily analysed
(Marcuello et al, 2004).
TS gene amplification and overexpression can lead to resistance
to TS-targeting chemotherapeutic drugs (5FU and fluorodeoxy-
uridine (FUDR)) (Copur et al, 1995; Davies et al, 1999; Wu and
Dolnick, 2003). Moreover, by hepatic arterial infusion (HAI) it is
possible to reach lower TS mRNA and higher ribonucleotide
reductase activity than with systemic chemotherapy (SC) (Kubota
et al, 2002).
HAI therapy could generate higher intracellular levels of 5FU
and FUDR metabolite, fluorodeoxyuridylate, locally (Gonen et al,
2003a). Among 135 patients randomly assigned to receive HAI vs
systemic bolus 5FU and leucovorin, overall survival was signifi-
cantly longer for HAI vs systemic treatment (P¼0.003), as was
time to hepatic progression (P¼0.03) (Kemeny et al, 2006). By
contrast, time to extrahepatic progression was significantly shorter
in the HAI group (P¼0.02).
In a previous study, Gonen et al (2003b) reported that patients
with resectable TS overexpressing (TSþ) liver metastases from
colorectal cancer have better overall survival (OS) when treated by
HAI plus SC rather than by SC alone. On the contrary, patients
with TS-negative metastatic colorectal cancer treated with SC plus
HAI had similar OS compared with SC alone. More interestingly,
in the study by Kemeny et al (2006), liver biopsies in the HAI
group, although based on small numbers (40 patients), demon-
strated that for patients with TS levels in tumour X4 the median
OS was 14 months, while for those with levels less than 4, median
OS was 24 months.
As previously reported (Alimonti et al, 2003), we think that,
regarding patients treated with SC, it could be interesting to
ascertain the role of the thymidine phosporylase (TP), the first
enzyme involved in the metabolic activation pathway of FU to
fluorodeoxyribonucleotides. Conversely, continuous HAI of FUDR
generates FUDR monophosphate via uptake and activation by
thymidine kinase and, unlike i.v bolus 5FU treatment, levels of TP
would not likely be of predictive value. Preoperative biopsies and
resection specimens from patients with stage II/III rectal
carcinoma receiving neoadjuvant 5FU-based chemoradiotherapy
have been recently studied for TS and TP protein expression by
immunohistochemistry, and results have been compared with
histopathologic tumour regression. A significant association was
observed between high TS expression in tumour biopsies as well as
resection specimens and nonresponse of the tumour to therapy
(P¼0.04), but low TP expression in the resection specimens
was significantly associated with lack of response (P¼0.02)
(Jakob et al, 2005). However, it is still controversial whether TP
expression in tumour is an independent factor that adds to TS
positivity in worsening the prognosis of patients with metastatic
colorectal cancer.
Interindividual variation in the activity of metabolising enzymes
can affect the extent of pyrimidine prodrug activation, acting on
the efficacy of chemotherapy treatment (Maring et al, 2005).
Patients with low levels of TP could be unable to properly
metabolise FU administered by i.v. systemic infusion. A repeat
polymorphism within the 50 UTR, that alters TS expression, has
been correlated with response and survival in colorectal cancer
patients receiving 5FU in several studies (Iacopetta et al, 2001).
Thus, the role of germline polymorphisms (uridine mono-
phosphate kinase (UMPK), orotate phosphoribosyl trans-
ferase (OPRT), TS, dihydropyrimidine dehydrogenase (DPD),
and methylene tetrahydrofolate reductase (MTHFR)), tumour-
specific somatic mutations and gene/protein expression levels
(OPRT, UMPK, TS, DPD, uridine phosphorylase, uridine kinase,
TP, thymidine kinase, deoxyuridine triphosphate nucleotide
hydrolase) must be taken into account in explaining variation in
anti-tumour efficacy and toxicity of 5F. Published online 17 October 2006
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